What Can Employers Do About High Drug Costs?
Which of your employer-sponsored health plan costs cause you the most headaches?
If you’re like 60% of the employers surveyed by the National Alliance of Healthcare Purchaser Coalitions, it’s the rising cost of prescription drugs.
A study by the Rand Corporation in 2021 found that drugs cost an average 256% more in the U.S. compared to 32 other countries. One such example of a high-cost drug is Zolgensma, a one-time curative therapy for spinal muscular atrophy, a rare genetic disorder that weakens muscles and can be fatal. A single treatment costs $2.1 million and may not be covered by insurance.
The reasons for high prescription drug costs are numerous and include:
- The costs of subsidizing research and development to make new drugs are figured into the cost of a drug. The pharmaceutical industry estimates that it costs about $2.6 billion to develop a new drug.
- Monopoly pricing power is used by pharmaceutical companies with drug patents and exclusive rights to price and sell their drugs for maximum profit.
- Medicare, the federal health insurance program for Americans 65 and older and those with certain disabilities, is the largest single payer for prescription drugs. Medicare is banned from negotiating drug prices sold through Medicare and cannot create a national Medicare formulary.
- Middlemen, which include health insurance companies, pharmacy benefit managers, wholesale pharmacies and retail pharmacies, also increase prices to cover their costs and make a profit.
- Patent “games,” sometimes referred to as “evergreening,” “pay-for-delay” or “withholding ingredients,” is when a drug company makes a small change to a patented drug in order to maintain its monopoly and control the price.
- Sometimes a company will make a payfor- delay deal to a generic drug company to postpone launching a competing, less expensive generic version.
- Generic drugs are usually less expensive than brand name drugs, but sometimes, if there are few competitors, they can be more expensive than the name brand.
- The U.S. does not regulate the drug prices to the extent found in other high-income countries.
Employer Solutions
There are a few things you can do to lower prescription drugs costs.
- Use Pharmacy benefit managers. PBMs negotiate discounts and rebates with manufacturers for the drugs they provide to pharmacies, doctors and hospitals. When it works, patients get lower costs, but some PBMs don’t pass the discounts on to patients. Employers are working to change the agreements with their PBMs to reduce waste and fraud and implement more effective strategies.
- Promote Preventative Care. The Centers for Disease Control and Prevention (CDC) reports that 75% of health care spending is due to chronic diseases that could be avoided by preventative care services. That is why three-quarters of employers offer a wellness benefit program. A Harvard University study estimates that for every dollar spent on a wellness program, healthcare costs can be lowered by $3.27. Another $2.73 could be saved in reduced absenteeism.
Emphasize the value of generic drugs. Generic drugs approved by The U.S. Food and Drug Administration have met the same rigid standards as brand name drugs. According to GoodRX Health, generic medications typically cost about 80 to 85% less than the same brand name drugs.
© 2022 SmartsPro publishing. All rights reserved.
About the Author
Share This Story
Related Blogs
RxDC Reporting: What Employers Should Do Before the June 1 Deadline
Each year, group health plans must report detailed prescription drug and healthcare spending data to the Centers for Medicare & Medicaid Services (CMS). This reporting—commonly referred to as RxDC reporting—is due by June 1 and applies to most employer-sponsored group health plans that offer prescription drug coverage.
Chronic Condition Management 2.0: GLP-1 Alternatives and New Digital Therapeutics
Chronic conditions have long been the primary driver of employer healthcare spending, but 2026 marks a turning point in how organizations are approaching prevention, treatment, and long-term management. With GLP-1 medications dominating headlines — and budgets — employers are urgently exploring complementary or alternative strategies that can improve outcomes without unsustainable cost growth. The result is a new wave of digital therapeutics, metabolic health programs, and integrated care models that promise a more balanced approach to chronic disease management.
The Return-to-Office Reset: How Benefits Are Being Re-Engineered in 2026
After several years of experimentation, many employers are tightening hybrid schedules or requiring more in-office days. This “return-to-office reset” is reshaping benefits strategies as organizations look for ways to support commuting employees, improve onsite experience, and maintain flexibility. What began as a workplace policy shift is now driving a broader rethinking of how benefits can reinforce culture, productivity, and retention.








